B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 187.6 DKK -2.75% Market Closed
Market Cap: 14.8B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Operating Margin
Bavarian Nordic A/S

11.9%
Current
-3%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.9%
=
Operating Profit
723.6m
/
Revenue
6.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
Bavarian Nordic A/S
CSE:BAVA
14.6B DKK
12%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country DK
Market Cap 14.6B DKK
Operating Margin
12%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 315.2B USD
Operating Margin
28%
Country US
Market Cap 141.9B USD
Operating Margin
19%
Country US
Market Cap 116.4B USD
Operating Margin
38%
Country US
Market Cap 104.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
14.6B DKK
Industry
Biotechnology

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BAVA Intrinsic Value
509.91 DKK
Undervaluation 63%
Intrinsic Value
Price
B

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.9%
=
Operating Profit
723.6m
/
Revenue
6.1B
What is the Operating Margin of Bavarian Nordic A/S?

Based on Bavarian Nordic A/S's most recent financial statements, the company has Operating Margin of 11.9%.